You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Biphase Extended Release Tablet Formulation for Nerve Agent Pretreatment

    SBC: Zymeron Corporation            Topic: CBD181004

    Nerve agents exert their toxic effect by binding to and inactivating enzyme acetylcholinesterase, a key enzymatic regulator of cholinergic neurotransmission. The binding becomes irreversible after a varying amount of time with nerve agents and this aging process limits the treatment window of oxime reactivators. To enhance the current antidote treatment of nerve agent autoinjectors, a pyridostigmi ...

    SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense
  2. Dual Formulation of Atropine/Scopolamine with Enhanced Stability

    SBC: Cmc Pharmaceuticals, Inc.            Topic: CBD181005

    CMC Pharmaceuticals, Inc. (Cleveland, OH) is proposing developing a stable, combination product of two small molecule drug candidates as a counter measure to chemical warfare nerve agents (NA). The combination product is expected to exploit complementary pharmacological profiles for optimal muscarinic receptor blockade and anticholinergic activity within the peripheral and central nervous system. ...

    SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense
  3. Field Portable Mass Spectrometry for Small Molecule Drugs in Clinical Samples

    SBC: Spectral Energies, LLC            Topic: CBD181006

    We propose a novel two-dimensional mass spectrometry (2D-MS) technique based on ion trap arrays to identify illicit and designer drugs. This approach will give an unprecedented multiplex advantage for miniature mass spectrometry, allowing novice field technicians to rapidly identify drugs affecting the central nervous system based on both the m/z ratio and fragmentation pattern of an ion. Towards ...

    SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense
  4. Bi-specific Antibodies Targeting Disease Caused by Encephalitic Alphaviruses

    SBC: BRHMS LLC            Topic: CBD181007

    Highly pathogenic alphaviruses like VEEV/EEV/WWEEV cause encephalitis in humans and equids. These infections are endemic in wide regions of the developing world. Translational research regarding these pathogens is focused on developing new strategies to detect, treat and ideally protect humans and animals from these infections. Gene-encoded antibodies against alphavirus E1/E2 surface proteins will ...

    SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense
  5. Augmented Reality Surgical Visualization

    SBC: CFD Research Corporation            Topic: DHA191001

    Care for the wounded Warfighters in austere and remote settings makes medical knowledge, skills and efficiency of the military medical professional paramount. For wounds that extend deep into internal anatomy, proper visualization of internal anatomy can

    SBIR Phase I 2019 Department of DefenseDefense Health Agency
  6. nXcomms: Intelligent Patient Simulation

    SBC: BioMojo, LLC            Topic: DHA191002

    BioMojo proposes to develop a language-based intelligent patient simulation platform for the purpose of providing students with a realistic training environment and instructors better control over the training environment involving simulated patients.

    SBIR Phase I 2019 Department of DefenseDefense Health Agency
  7. Intelligent Patient Simulation Platform

    SBC: Sharp Vision Software LLC            Topic: DHA191002

    A proof-of-concept research on Intelligent Patient Platform is proposed with the goal to improve healthcare training experience by adding natural language capability to patient simulators by leveraging the latest artificial intelligent technologies so tha

    SBIR Phase I 2019 Department of DefenseDefense Health Agency
  8. ReMIDe (Reliable Medical Information Delivery in DIL environments)

    SBC: Architecture Technology, Inc.            Topic: DHA191004

    The Defense Health Agency has identified the need for an advanced computing and networking capability to support unfettered operation of Electronic Medical Records (EMR) systems in delayed/disconnected, intermittently-connected, low-bandwidth (DIL) enviro

    SBIR Phase I 2019 Department of DefenseDefense Health Agency
  9. Novel Fluorescence Lysosomal Yeast (FLY) Portable Biosensor for General Water Toxicity Testing

    SBC: NANOHMICS INC            Topic: DHA191006

    Nanohmics proposes to develop a radically new type of general water toxicity monitor based on the widely published principle that many eukaryotic (including yeast) cell lysosomes swell and increase in numbers in response to pollutants in water within 30-6

    SBIR Phase I 2019 Department of DefenseDefense Health Agency
  10. Development of PRESTO, a Software Platform for Automated Prosthetic and Orthotic Interface Design

    SBC: ADA Technologies, Inc.            Topic: DHA191009

    Veterans with amputations are relatively common as a result of war and peace keeping efforts. The civilian amputee population is also steadily growing as a result of vascular disease. For many years, there has been an emphasis on the development of prosth

    SBIR Phase I 2019 Department of DefenseDefense Health Agency
US Flag An Official Website of the United States Government